Fantastic new development for Cystic Fibrosis!
Fantastic new development for Cystic Fibrosis!
EU Approval for TOBI Podhaler comes as great news for cystic fibrosis patients across the country. TOBI Podhaler, an inhaled therapy for patients with cystic fibrosis, is to be used with patients 6years+ for suppression of chronic lung infections.
“With the approval of the TOBI Podhaler in Europe, and innovative version of an established treatment has become available that will improve the delivery of tobramycin and should have a positive impact on patients’ quality of life”, said Professor Stuart Elborn, President of the European Cystic Fibrosis Society and Professor of Respiratory Medicine at Queens University.
Dr. Greg Hays of Novartis said “It is an important symbol of our long term commitment to improving the quality of care for patients with this serious and potentially life-threatening disease.”
